Safety, Pharmacokinetics, and Efficacy of (+/−)-β-2′,3′-Dideoxy-5-Fluoro-3′-Thiacytidine with Efavirenz and Stavudine in Antiretroviral-Naïve Human Immunodeficiency Virus-Infected Patients

Racivir [RCV; (+/−)-β-2′,3′-dideoxy-5-fluoro-3′-thiacytidine], a 50:50 racemic mixture of the two β nucleoside enantiomers, is currently in development for the treatment of human immunodeficiency virus type 1 (HIV-1) infections. RCV was administered once a day orally for 14 days at doses of 200, 400...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Herzmann, C., Arastèh, K., Murphy, R. L., Schulbin, H., Kreckel, P., Drauz, D., Schinazi, R. F., Beard, A., Cartee, L., Otto, M. J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2005
Schlagworte:
Antiviral Agents
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC1168662/
https://ncbi.nlm.nih.gov/pubmed/15980356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.49.7.2828-2833.2005
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge